Renalytix is a pioneering company in the emerging field of bioprognosis for kidney health. Its innovative solution allows for early-stage risk assessment, helping patients manage their condition before it progresses too far. Renalytix is a global leader in this space and is listed on both the London Stock Exchange and NASDAQ.